They are particularly being examined in cancers where AXL overexpression is associated with poor prognosis and resistance to standard treatments, such as non-small cell lung cancer, triple-negative breast cancer, and acute myeloid leukaemia [42, 43]. The gene discussed is AXL; the disease is acute myeloid leukemia.